During the past decade, Van Weel-Bethesda Ziekenhuis conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 3 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 1 clinical trials were completed. i.e. 14.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Van Weel-Bethesda Ziekenhuis" #1 sponsor was "Borstkanker Onderzoek Groep" with 2 trials, followed by "Pfizer" with 2 trials sponsored, "Stichting Hemato-Oncologie voor Volwassenen Nederland" with 2 trials sponsored, "Amgen" with 1 trials sponsored and "Bayer" with 1 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Van Weel-Bethesda Ziekenhuis" #1 collaborator was "Australasian Leukaemia and Lymphoma Group" with 1 trials as a collaborator, "BOOG Study Center" with 1 trials as a collaborator, "Central European Myeloma Study Group" with 1 trials as a collaborator, "Coordinating Centre for Clinical Trials, Charité" with 1 trials as a collaborator and "DSMM (Deutsche Studiengruppe Multiples Myelom)" with 1 trials as a collaborator. Other collaborators include 16 different institutions and companies that were collaborators in the rest 26 trials.

According to Clinical.Site data, the most researched conditions in "Van Weel-Bethesda Ziekenhuis" are "Atrial Fibrillation" (2 trials), "Breast Cancer" (2 trials), "Cardiovascular Disease" (2 trials), "Atherosclerotic Cardiovascular Disease" (1 trials) and "Breast Neoplasm Female" (1 trials). Many other conditions were trialed in "Van Weel-Bethesda Ziekenhuis" in a lesser frequency.

Most popular intervention types in "Van Weel-Bethesda Ziekenhuis" are "Drug" (10 trials), "Other" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "bococizumab (PF-04950615)" (2 trials), "1 or 2 cycle(s) HDM (High Dose Melphalan)" (1 trials), "2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)" (1 trials) and "Apixaban" (1 trials). Other intervention names were less common.

The vast majority of trials in "Van Weel-Bethesda Ziekenhuis" are 14 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Van Weel-Bethesda Ziekenhuis". undefined are not yet recruiting, 5 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Van Weel-Bethesda Ziekenhuis, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Van Weel-Bethesda Ziekenhuis, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".